These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 29935955)
21. Resistin Gene Expression is Downregulated in CD4(+) T Helper Lymphocytes and CD14(+) Monocytes in Rheumatoid Arthritis Responding to TNF-α Inhibition. Nagaev I; Andersen M; Olesen MK; Nagaeva O; Wikberg J; Mincheva-Nilsson L; Andersen GN Scand J Immunol; 2016 Oct; 84(4):229-36. PubMed ID: 27434862 [TBL] [Abstract][Full Text] [Related]
22. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195 [TBL] [Abstract][Full Text] [Related]
23. Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada. Weijers L; Baerwald C; Mennini FS; Rodríguez-Heredia JM; Bergman MJ; Choquette D; Herrmann KH; Attinà G; Nappi C; Merino SJ; Patel C; Mtibaa M; Foo J Rheumatol Int; 2017 Jul; 37(7):1111-1123. PubMed ID: 28560470 [TBL] [Abstract][Full Text] [Related]
24. T cell signal transducer and activator of transcription (STAT) 4 and 6 are affected by adalimumab therapy in rheumatoid arthritis. Aerts NE; Ebo DG; Bridts CH; Stevens WJ; De Clerck LS Clin Exp Rheumatol; 2010; 28(2):208-14. PubMed ID: 20483042 [TBL] [Abstract][Full Text] [Related]
25. Effect of serum anti-tumour necrosis factor (TNF) drug trough concentrations and antidrug antibodies (ADAb) to further anti-TNF short-term effectiveness after switching in rheumatoid arthritis and axial spondyloarthritis. Vincent FB; Pavy S; Krzysiek R; Lequerré T; Sellam J; Taoufik Y; Mariette X; Miceli-Richard C Joint Bone Spine; 2016 Oct; 83(5):595-7. PubMed ID: 27066773 [No Abstract] [Full Text] [Related]
26. Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors. Anderson P; Louie J; Lau A; Broder M Curr Rheumatol Rep; 2005 Mar; 7(1):3-9. PubMed ID: 15760575 [No Abstract] [Full Text] [Related]
27. TNF inhibitors: a new age in rheumatoid arthritis treatment. Anderson DL Am J Nurs; 2004 Feb; 104(2):60-8; quiz 68-9. PubMed ID: 14767382 [No Abstract] [Full Text] [Related]
28. Adalimumab therapy in rheumatoid arthritis. Keystone E; Haraoui B Rheum Dis Clin North Am; 2004 May; 30(2):349-64, vii. PubMed ID: 15172045 [TBL] [Abstract][Full Text] [Related]
29. Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy. Furst DE; Kavanaugh A; Florentinus S; Kupper H; Karunaratne M; Birbara CA Rheumatology (Oxford); 2015 Dec; 54(12):2188-97. PubMed ID: 26199453 [TBL] [Abstract][Full Text] [Related]
30. Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis. Cannon GW; DuVall SL; Haroldsen CL; Caplan L; Curtis JR; Michaud K; Mikuls TR; Reimold A; Collier DH; Harrison DJ; Joseph GJ; Sauer BC J Rheumatol; 2014 Oct; 41(10):1935-43. PubMed ID: 25128516 [TBL] [Abstract][Full Text] [Related]
31. Immediate local and systemic hypersensitivity due to etanercept and adalimumab. Hansel K; Bianchi L; Tramontana M; Balato A; Scala E; Brozzi J; Stingeni L J Allergy Clin Immunol Pract; 2019 Feb; 7(2):726-727. PubMed ID: 30006049 [No Abstract] [Full Text] [Related]